A total of 139 participants have so far been enrolled in the clinical trial on the use of sleep-aid supplement melatonin as adjuvant treatment for coronavirus disease (COVID-19) in patients with pneumonia, the Department of Science and Technology (DOST) said.
(Photo by James Yarema on Unsplash)
Published May 7, 2021, 3:15 PM
The recruitment of participants for clinical trial on the use of sleep-aid supplement melatonin as adjuvant treatment for coronavirus disease (COVID-19) in patients with pneumonia is ongoing, the Department of Science and Technology (DOST) has disclosed.
DOST Secretary Fortunato “Boy” T. de la Peña said the melatonin clinical trial is headed by Dr. Camilo C. Roa Jr. of the Manila Doctors Hospital and is implemented for nine months, from Sept. 7, 2020 to June 6, 2021.
(Manila Bulletin File Photo)
“Currently, recruitment of participants is ongoing,” he said.
He said the project has already started the recruitment in 12 out of the 17 hospital sites.